Skip to main content
Ebola vaccine

Coronavirus and Ebola Show We Can’t Leave Vaccine Development to Big Pharma

Juliana Broad writes about the botched development of the Ebola vaccine, citing the work of The Democracy Collaborative’s Dana Brown on the necessity of public pharma.

Five years after an Ebola epidemic killed more than 11,000 people across West Africa, the U.S. Food and Drug Administration announced at the end of December 2019 that Merck, the behemoth, for-profit pharmaceutical company based in New Jersey, had received approval for an Ebola vaccine.

But this is hardly a success story. In fact, the saga behind the vaccine’s development sheds light on how involving private pharmaceutical companies may have obstructed the vaccine’s progress, profiting from publicly funded research only once the vaccine’s development proved to be lucrative business.

A new report, published in the Journal of Law and the Biosciences, details how the Ebola vaccine, Ervebo, was almost entirely researched and developed using public money, challenging the common assumption that only private, profit-driven companies are able to bring drugs to market.

Matthew Herder, one of the authors of the report, noted parallels between the Ebola response and the current coronavirus outbreak. “It seems fairly clear that the same approach — of patenting and licensing out to the private sector — is being relied upon by the public sector to advance vaccine development,” he told Truthout via email.

Herder emphasizes that their case study on Ebola cannot be generalized. Nonetheless, the authors raise a particularly urgent question as the U.S. struggles to marshal a response to a spreading coronavirus outbreak: Could the Ebola vaccine have been produced earlier, potentially saving thousands of lives, if researchers could have avoided the profit-driven trappings of private pharmaceutical companies?

Read the entire article at Truthout.

Publication date: 2020-03-09
Parent publication: Truthout
Publication URL: https://truthout.org/articles/coronavirus-and-ebola-show-we-cant-leave-vaccine-development-to-big-pharma/

More related work

Illustration courtesy of United Nations

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. But the COVID-19

read more
Neil McInroy (Source: Coop News)

Neil McInroy joins TDC to advise stepped-up community wealth building program

The former CEO of a leading UK economic think tank will be central in helping build capacity to offer powerful new technical assistance to cities and local authorities pursuing community wealth building strategies.

read more
Default Image

The Democracy Collaborative and The Democracy Collaborative Workers' Union agree to fair severance package for laid-off staff

TDC and union members have agreed to a package of protections that goes well beyond the baseline severance provisions for layoffs agreed to in TDC’s union contract.

read more